Total‐, LDL‐, and HDL‐cholesterol, apolipoproteins, and triglycerides with risk of total and fatal prostate cancer in Black and White men in the ARIC study
- 8 May 2023
- journal article
- research article
- Published by Wiley in The Prostate
- Vol. 83 (11) , 1046-1059
Abstract
Background: Cholesterol reduction is considered a mechanism through which cholesterol‐lowering drugs including statins are associated with a reduced aggressive prostate cancer risk. While prior cohort studies found positive associations between total cholesterol and more advanced stage and grade in White men, whether associations for total cholesterol, low (LDL)‐ and high (HDL)‐density lipoprotein cholesterol, apolipoprotein B (LDL particle) and A1 (HDL particle), and triglycerides are similar for fatal prostate cancer and in Black men, who experience a disproportionate burden of total and fatal prostate cancer, is unknown.Methods: We conducted a prospective study of 1553 Black and 5071 White cancer‐free men attending visit 1 (1987–1989) of the Atherosclerosis Risk in Communities Study. A total of 885 incident prostate cancer cases were ascertained through 2015, and 128 prostate cancer deaths through 2018. We estimated multivariable‐adjusted hazard ratios (HRs) of total and fatal prostate cancer per 1‐standard deviation increments and for tertiles (T1–T3) of time‐updated lipid biomarkers overall and in Black and White men.Results: Greater total cholesterol concentration (HR per‐1 SD = 1.25; 95% CI = 1.00–1.58) and LDL cholesterol (HR per‐1 SD = 1.26; 95% CI = 0.99–1.60) were associated with higher fatal prostate cancer risk in White men only. Apolipoprotein B was nonlinearly associated with fatal prostate cancer overall (T2 vs. T1: HR = 1.66; 95% CI = 1.05–2.64) and in Black men (HR = 3.59; 95% CI = 1.53–8.40) but not White men (HR = 1.13; 95% CI = 0.65–1.97). Tests for interaction by race were not statistically significant.Conclusions: These findings may improve the understanding of lipid metabolism in prostate carcinogenesis by disease aggressiveness, and by race while emphasizing the importance of cholesterol control.Keywords
Funding Information
- National Heart, Lung, and Blood Institute (HHSN268201700001I, HHSN268201700002I, HHSN268201700003I, HHSN268201700004I, HHSN268201700005I)
This publication has 47 references indexed in Scilit:
- Trends in Lipids and Lipoproteins in US Adults, 1988-2010JAMA, 2012
- Statin Use and Risk of Prostate Cancer: A Meta-Analysis of Observational StudiesPLOS ONE, 2012
- Use of Fibrates and Cancer Risk: A Systematic Review and Meta-Analysis of 17 Long-Term Randomized Placebo-Controlled TrialsPLOS ONE, 2012
- Lack of Effect of Lowering LDL Cholesterol on Cancer: Meta-Analysis of Individual Data from 175,000 People in 27 Randomised Trials of Statin TherapyPLOS ONE, 2012
- Minimal detection bias in the inverse association between statin drug use and advanced prostate cancer risk: A simulation studyCancer Epidemiology, 2011
- Modifiable risk factors for prostate cancer mortality in London: forty years of follow-up in the Whitehall studyCancer Causes & Control, 2010
- Men with Low Serum Cholesterol Have a Lower Risk of High-Grade Prostate Cancer in the Placebo Arm of the Prostate Cancer Prevention TrialCancer Epidemiology, Biomarkers & Prevention, 2009
- Association between plasma total cholesterol concentration and incident prostate cancer in the CLUE II cohortCancer Causes & Control, 2009
- Racial Differences in Risk of Prostate Cancer Associated With Metabolic SyndromeUrology, 2009
- Association between plasma cholesterol and prostate cancer in the PSA eraInternational Journal of Cancer, 2008